Molecular basis for specificity in the druggable kinome : sequence-based analysis

MOTIVATION Rational design of kinase inhibitors remains a challenge partly because there is no clear delineation of the molecular features that direct the pharmacological impact towards clinically relevant targets. Standard factors governing ligand affinity, such as potential for intermolecular hydrophobic interactions or for intermolecular hydrogen bonding do not provide good markers to assess cross reactivity. Thus, a core question in the informatics of drug design is what type of molecular similarity among targets promotes promiscuity and what type of molecular difference governs specificity. This work answers the question for a sizable screened sample of the human pharmacokinome including targets with unreported structure. RESULTS We show that drug design aimed at promoting pairwise interactions between ligand and kinase target actually fosters promiscuity because of the high conservation of the partner groups on or around the ATP-binding site of the kinase. Alternatively, we focus on a structural marker that may be reliably determined from sequence and measures dehydration propensities mostly localized on the loopy regions of kinases. Based on this marker, we construct a sequence-based kinase classifier that enables the accurate prediction of pharmacological differences. Our indicator is a microenvironmental descriptor that quantifies the propensity for water exclusion around preformed polar pairs. The results suggest that targeting polar dehydration patterns heralds a new generation of drugs that enable a tighter control of specificity than designs aimed at promoting ligand-kinase pairwise interactions. AVAILABILITY The predictor of polar hot spots for dehydration propensity, or solvent-accessible hydrogen bonds in soluble proteins, named YAPView, may be freely downloaded from the University of Chicago website http://protlib.uchicago.edu/dloads.html. SUPPLEMENTARY INFORMATION Supplementary data are available at Bioinformatics online.

[1]  B. Erman,et al.  Information‐theoretical entropy as a measure of sequence variability , 1991, Proteins.

[2]  L. Wodicka,et al.  A small molecule–kinase interaction map for clinical kinase inhibitors , 2005, Nature Biotechnology.

[3]  Richard Bonneau,et al.  De novo prediction of three-dimensional structures for major protein families. , 2002, Journal of molecular biology.

[4]  A Keith Dunker,et al.  Combining prediction, computation and experiment for the characterization of protein disorder. , 2004, Current opinion in structural biology.

[5]  Ariel Fernández,et al.  Keeping dry and crossing membranes , 2004, Nature Biotechnology.

[6]  Ariel Fernández,et al.  A priori inference of cross reactivity for drug-targeted kinases. , 2006, Journal of medicinal chemistry.

[7]  M. Vieth,et al.  Kinomics-structural biology and chemogenomics of kinase inhibitors and targets. , 2004, Biochimica et biophysica acta.

[8]  C W Hogue,et al.  Cn3D: a new generation of three-dimensional molecular structure viewer. , 1997, Trends in biochemical sciences.

[9]  C. Chothia,et al.  Hydrophobic bonding and accessible surface area in proteins , 1974, Nature.

[10]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[11]  Werner Braun,et al.  Exact and efficient analytical calculation of the accessible surface areas and their gradients for macromolecules , 1998 .

[12]  John P. Overington,et al.  Can we rationally design promiscuous drugs? , 2006, Current opinion in structural biology.

[13]  H. Scheraga,et al.  Accessible surface areas as a measure of the thermodynamic parameters of hydration of peptides. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[14]  Ariel Fernández,et al.  Dynamics of hydrogen bond desolvation in protein folding. , 2002, Journal of molecular biology.

[15]  Lars Malmström,et al.  Prediction of CASP6 structures using automated robetta protocols , 2005, Proteins.

[16]  J. Kuriyan,et al.  The Conformational Plasticity of Protein Kinases , 2002, Cell.

[17]  J. Thompson,et al.  Using CLUSTAL for multiple sequence alignments. , 1996, Methods in enzymology.

[18]  B. Shoichet,et al.  High-throughput assays for promiscuous inhibitors , 2005, Nature chemical biology.

[19]  P. Cohen,et al.  The specificities of protein kinase inhibitors: an update. , 2003, The Biochemical journal.

[20]  R. Nussinov,et al.  Protein–protein interactions: Structurally conserved residues distinguish between binding sites and exposed protein surfaces , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[21]  B. Druker,et al.  Molecularly targeted therapy: have the floodgates opened? , 2004, The oncologist.

[22]  Lina Souan,et al.  Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. , 2004, Blood.

[23]  Kevan M Shokat,et al.  Features of selective kinase inhibitors. , 2005, Chemistry & biology.

[24]  Ariel Fernández,et al.  Molecular dimension explored in evolution to promote proteomic complexity. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[25]  T L Blundell,et al.  Protein structure--based drug design. , 1994, Annual review of biophysics and biomolecular structure.

[26]  V. Laudet,et al.  Ligand binding and nuclear receptor evolution , 2000, BioEssays : news and reviews in molecular, cellular and developmental biology.